Literature DB >> 20467693

Rationalization of the inhibition activity of structurally related organometallic compounds against the drug target cathepsin B by DFT.

Angela Casini1, Fabio Edafe, Mikael Erlandsson, Luca Gonsalvi, Antonella Ciancetta, Nazzareno Re, Andrea Ienco, Luigi Messori, Maurizio Peruzzini, Paul J Dyson.   

Abstract

A series of organometallic compounds of general formula [(arene)M(PTA)(n)X(m)]Y (arene = eta(6)-C(10)H(14), eta-C(5)Me(5)); M = Ru(ii), Os(ii), Rh(iii) and Ir(iii); X = Cl, mPTA; Y = OTf, PF(6)) have been screened for their cytotoxicity and ability to inhibit cathepsin B in vitro, in comparison to the antimetastatic compound NAMI-A. The Ru and Os analogues and NAMI-A showed similar enzyme inhibition properties (with IC(50) values in the low muM range), whereas the Rh(iii) and Ir(iii) compounds were inactive. In order to build up a rational for the observed differences, DFT calculations of the metal complexes adducts with N-acetyl-l-cysteine-N'-methylamide, a mimic for the Cys residue in the cathepsin B active site, were performed to provide insights into binding thermodynamics in solution. Initial structure-activity relationships have been defined with the calculated binding energies of the M-S bonds correlating well with the observed inhibition properties of the compounds.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20467693     DOI: 10.1039/c003218b

Source DB:  PubMed          Journal:  Dalton Trans        ISSN: 1477-9226            Impact factor:   4.390


  7 in total

1.  A QM/MM study of the binding of RAPTA ligands to cathepsin B.

Authors:  Antonella Ciancetta; Samuel Genheden; Ulf Ryde
Journal:  J Comput Aided Mol Des       Date:  2011-06-24       Impact factor: 3.686

2.  Potent Half-Sandwich Iridium(III) Anticancer Complexes Containing CN-Chelated and Pyridine Ligands.

Authors:  Zhe Liu; Isolda Romero-Canelón; Abraha Habtemariam; Guy J Clarkson; Peter J Sadler
Journal:  Organometallics       Date:  2014-09-09       Impact factor: 3.876

3.  A ruthenium anticancer compound interacts with histones and impacts differently on epigenetic and death pathways compared to cisplatin.

Authors:  Cynthia Licona; Marie-Elodie Spaety; Antonelle Capuozzo; Moussa Ali; Rita Santamaria; Olivier Armant; Francois Delalande; Alain Van Dorsselaer; Sarah Cianferani; John Spencer; Michel Pfeffer; Georg Mellitzer; Christian Gaiddon
Journal:  Oncotarget       Date:  2017-01-10

4.  Similarities and differences in d6 low-spin ruthenium, rhodium and iridium half-sandwich complexes: synthesis, structure, cytotoxicity and interaction with biological targets.

Authors:  Agnieszka Gilewska; Barbara Barszcz; Joanna Masternak; Katarzyna Kazimierczuk; Jerzy Sitkowski; Joanna Wietrzyk; Eliza Turlej
Journal:  J Biol Inorg Chem       Date:  2019-05-21       Impact factor: 3.358

5.  Antiproliferative Ruthenium Complexes Containing Curcuminoid Ligands Tested In Vitro on Human Ovarian Tumor Cell Line A2780, towards Their Capability to Modulate the NF-κBTranscription Factor, FGF-2 Growth Factor, and MMP-9 Pathway.

Authors:  Janka Leskovská; Natalia Miklášová; Paul Milan Kubelac; Patriciu Achimaş-Cadariu; Jindra Valentová; Mário Markuliak; Eva Fischer-Fodor
Journal:  Molecules       Date:  2022-07-18       Impact factor: 4.927

Review 6.  Organoiridium complexes: anticancer agents and catalysts.

Authors:  Zhe Liu; Peter J Sadler
Journal:  Acc Chem Res       Date:  2014-02-20       Impact factor: 22.384

7.  Tethering (Arene)Ru(II) Acylpyrazolones Decorated with Long Aliphatic Chains to Polystyrene Surfaces Provides Potent Antibacterial Plastics.

Authors:  Corrado Di Nicola; Fabio Marchetti; Riccardo Pettinari; Alessia Tombesi; Claudio Pettinari; Iolanda Grappasonni; Paul J Dyson; Stefania Scuri
Journal:  Materials (Basel)       Date:  2020-01-22       Impact factor: 3.623

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.